CST and AstraZeneca Expand Research Agreement
Cell Signaling Technology and AstraZeneca this week signed a second agreement expanding upon a pilot study for phosphoproteomic profiling, CST said recently.
Under the terms of the new agreement, AstraZeneca will use CST's PhosphoScan technology to identify phosphorylation profiles and prospective biomarkers of kinase-targeted lead compounds, CST said. Financial terms were not disclosed.
Definiens to Provide Pfizer with Imaging Software